Stephens analyst Chris Cooley raised his price target on STERIS shares to $150 from $135 after the company reported Q4 results that topped consensus, noting that all four of the its business segments had better than expected revenue growth and increased operating margins. Cooley, who said he is confident STERIS can either meet or exceed its FY20 guidance, keeps an Overweight rating on the shares, which he continues to view as a “core holding.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.